A study published in The Lancet is the first clinical trial to show that immunisation with a new typhoid conjugate vaccine (TCV) is safe, well tolerated and will have significant impact on disease incidence in typhoid-endemic areas that introduce the vaccine.
A new typhoid vaccine for both adults and children has been proven by Oxford researchers, including Prof Brian Angus, to be safe and effective in preventing the disease.
